Wiki source
Longevity Pharma Pipeline
A read-only view of this entry as wiki markup. This atlas is curated, so editing is disabled — but the source shows exactly how the page is structured.
# Longevity Pharma Pipeline Portal: Future Pharma Stage: Mixed clinical maturity Evidence: Early human Template: Drug platform Risk: Moderate Reversibility: Context dependent Last reviewed: Jun 2026 == Summary == Aging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints. == Key takeaways == * Most products will enter through specific diseases, not aging as a broad claim. * Combination strategies may matter because aging mechanisms reinforce one another. * Regulatory endpoints and payer logic are as important as biological plausibility. == Pipeline logic == The longevity pipeline includes senescence drugs, metabolic modulators, immune rejuvenation, mitochondrial interventions, proteostasis tools, and regenerative signals. Aging is not yet a simple drug indication in most systems, so companies often target diseases where aging biology is a major driver. == Evidence problem == The ideal trial would show that an intervention delays multiple diseases or preserves function. That is expensive and slow. Intermediate biomarkers can accelerate development, but only if they predict outcomes that patients and regulators care about. == Watchlist == * Prevention endpoints * Biomarker qualification * Combination trials * Payer incentives == References == * TAME and geroscience trials — Barzilai et al., Cell Metabolism, 2016. https://pubmed.ncbi.nlm.nih.gov/27304507/. Use for the regulatory and trial-design logic behind metformin as a geroscience prototype. * Surrogate endpoint standards — U.S. FDA surrogate endpoint resources. https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development. Use for distinguishing biomarkers from accepted clinical benefit endpoints. == Categories == [[Category:Future Pharma]] [[Category:geroprotectors]] [[Category:trials]] [[Category:drug development]]